Ethics in preventive HIV vaccine research

Ruth Macklin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalHIV Therapy
Volume3
Issue number3
DOIs
StatePublished - 2009

Fingerprint

AIDS Vaccines
Ethics
Vaccines
Research
Hope
HIV Infections
Placebos
HIV
Control Groups

Keywords

  • Access to antiretrovirals
  • Ethical standards
  • HIV preventive vaccines
  • Placebo controls
  • Standard of prevention
  • UNAIDS/WHO guidance document

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology
  • Dermatology

Cite this

Ethics in preventive HIV vaccine research. / Macklin, Ruth.

In: HIV Therapy, Vol. 3, No. 3, 2009, p. 229-236.

Research output: Contribution to journalArticle

Macklin, Ruth. / Ethics in preventive HIV vaccine research. In: HIV Therapy. 2009 ; Vol. 3, No. 3. pp. 229-236.
@article{523eaf3746484619b41054736492184c,
title = "Ethics in preventive HIV vaccine research",
abstract = "It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?",
keywords = "Access to antiretrovirals, Ethical standards, HIV preventive vaccines, Placebo controls, Standard of prevention, UNAIDS/WHO guidance document",
author = "Ruth Macklin",
year = "2009",
doi = "10.2217/hiv.09.7",
language = "English (US)",
volume = "3",
pages = "229--236",
journal = "HIV Therapy",
issn = "1758-4310",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Ethics in preventive HIV vaccine research

AU - Macklin, Ruth

PY - 2009

Y1 - 2009

N2 - It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?

AB - It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?

KW - Access to antiretrovirals

KW - Ethical standards

KW - HIV preventive vaccines

KW - Placebo controls

KW - Standard of prevention

KW - UNAIDS/WHO guidance document

UR - http://www.scopus.com/inward/record.url?scp=67149120653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149120653&partnerID=8YFLogxK

U2 - 10.2217/hiv.09.7

DO - 10.2217/hiv.09.7

M3 - Article

VL - 3

SP - 229

EP - 236

JO - HIV Therapy

JF - HIV Therapy

SN - 1758-4310

IS - 3

ER -